Video
Dr. Earle Burgess on the next steps with PARP inhibitors in prostate cancer
Author(s):
Video Player is loading.
Earle Burgess, MD, associate professor of medicine, Levine Cancer Institute, Atrium Health, shares his expertise on what the next steps should be with PARP inhibitors in prostate cancer. The PARP inhibitors olaparib (Lynparza) and rucaparib (Rubraca) are approved by the FDA for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC), and other PARP agents are moving through the pipeline.
Related Videos
Timothy Lyon, MD, on recent change to outpatient complications metric in urology rankings
Neeraj Agarwal, MD, on talazoparib/enzalutamide efficacy by HRR gene mutation status
Jason Hafron, MD, considers the future for AI in urology
Sima Porten, MD, discusses the need to educate on the firefighter-bladder cancer link
Eugene Cone, MD, outlines potential impact of Expanded Access Program for rBCG
Investigators evaluate tamsulosin use in pediatric patients
Ruchika Talwar, MD, on how urologists can get involved in advocacy
Chad Ellimoottil, MD, on how urologists should approach telehealth in changing policy environment
How recombinant BCG could ease strain of supply issues
Katherine Chan, MD, on viral vs non-viral vectors in bladder cancer
Related Content
